164 related articles for article (PubMed ID: 12149223)
1. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
Gorgun G; Foss F
Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of rexinoids.
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S21-5. PubMed ID: 16516672
[TBL] [Abstract][Full Text] [Related]
3. A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma.
Foss F; Demierre MF; DiVenuti G
Blood; 2005 Jul; 106(2):454-7. PubMed ID: 15811959
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of VD-induced monocytic leukemia cell differentiation by retinoids involves both RAR and RXR signaling pathways.
Defacque H; Sévilla C; Piquemal D; Rochette-Egly C; Marti J; Commes T
Leukemia; 1997 Feb; 11(2):221-7. PubMed ID: 9009084
[TBL] [Abstract][Full Text] [Related]
5. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.
Fitzgerald P; Teng M; Chandraratna RA; Heyman RA; Allegretto EA
Cancer Res; 1997 Jul; 57(13):2642-50. PubMed ID: 9205071
[TBL] [Abstract][Full Text] [Related]
7. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
Jurutka PW; Wagner CE
Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with denileukin diftitox (ONTAK).
Foss F
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S11-6. PubMed ID: 16516670
[TBL] [Abstract][Full Text] [Related]
9. Receptor mechanisms mediating differentiation and proliferation effects of retinoids on neuroblastoma cells.
Hewson QC; Lova PE; Malcolm AJ; Pearson AD; Redfern CP
Neurosci Lett; 2000 Jan; 279(2):113-6. PubMed ID: 10674634
[TBL] [Abstract][Full Text] [Related]
10. Denileukin diftitox.
Figgitt DP; Lamb HM; Goa KL
Am J Clin Dermatol; 2000; 1(1):67-72; discussion 73. PubMed ID: 11702307
[TBL] [Abstract][Full Text] [Related]
11. Retinoic acid receptor- and retinoid X receptor-selective retinoids activate signaling pathways that converge on AP-1 and inhibit squamous differentiation in human bronchial epithelial cells.
Lee HY; Dawson MI; Walsh GL; Nesbitt JC; Eckert RL; Fuchs E; Hong WK; Lotan R; Kurie JM
Cell Growth Differ; 1996 Aug; 7(8):997-1004. PubMed ID: 8853895
[TBL] [Abstract][Full Text] [Related]
12. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells.
Hembree JR; Agarwal C; Beard RL; Chandraratna RA; Eckert R
Cancer Res; 1996 Apr; 56(8):1794-9. PubMed ID: 8620495
[TBL] [Abstract][Full Text] [Related]
13. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
[TBL] [Abstract][Full Text] [Related]
14. Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid x receptor selectivity and effects on metabolic enzymes.
Howell SR; Shirley MA; Ulm EH
Drug Metab Dispos; 1998 Mar; 26(3):234-9. PubMed ID: 9492386
[TBL] [Abstract][Full Text] [Related]
15. Denileukin diftitox as novel targeted therapy for lymphoid malignancies.
Wong BY; Gregory SA; Dang NH
Cancer Invest; 2007 Sep; 25(6):495-501. PubMed ID: 17882663
[TBL] [Abstract][Full Text] [Related]
16. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.
Vu-Dac N; Gervois P; Torra IP; Fruchart JC; Kosykh V; Kooistra T; Princen HM; Dallongeville J; Staels B
J Clin Invest; 1998 Aug; 102(3):625-32. PubMed ID: 9691099
[TBL] [Abstract][Full Text] [Related]
17. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
18. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.
Attia P; Maker AV; Haworth LR; Rogers-Freezer L; Rosenberg SA
J Immunother; 2005; 28(6):582-92. PubMed ID: 16224276
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.
Kuzel TM; Li S; Eklund J; Foss F; Gascoyne R; Abramson N; Schwerkoske JF; Weller E; Horning SJ
Leuk Lymphoma; 2007 Dec; 48(12):2397-402. PubMed ID: 17943599
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
